A rare lung disease often terminal, idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease affecting the lung interstitium. Patients diagnosed with IPF suffer an extreme lung deterioration resulting a decline in the lung functioning.

1. Idiopathic Pulmonary Fibrosis Therapeutic Market -
Global Industry Analysis, Size, Share, Growth, Trends,
and Forecast 2016 – 2024
A rare lung disease often terminal, idiopathic pulmonary fibrosis (IPF) is an interstitial
lung disease affecting the lung interstitium. Patients diagnosed with IPF suffer an
extreme lung deterioration resulting a decline in the lung functioning. IPF causes
'pulmonary fibrosis', which basically means damaging of the lung tissues. Breathing
distress is the most common intricacy involved with idiopathic pulmonary fibrosis.
The cause of idiopathic pulmonary fibrosis still remains unknown, however, it is
mostly linked with excessive inhalation of smoke or dust, exposure to unhealthy gases
and chemicals and smoking of cigarettes. IPF may also be caused due to genetic
predisposition or develop from other lung condition.
Some of the medical conditions, which may develop in a patient with idiopathic
pulmonary fibrosis (IPF) include obstructive sleep apnea, chronic obstructive
pulmonary disease, coronary artery disease and gastro oesophagal reflux disease. A set
of guidelines has been released for managing such conditions accordingly.
Idiopathic Pulmonary Fibrosis Therapeutic Market Trends
In the recent years, higher incidence of idiopathic pulmonary fibrosis has been
noticed, which has fueled the demand for idiopathic pulmonary fibrosis therapeutics.
The introduction of novel medicines and advancement in treatment methods of the
disease has further supplemented the overall growth of the market. Nintedanib and
Pirfenidone are the two most common anti-fibrotic drugs used for the treatment of
idiopathic pulmonary fibrosis.
There is no absolute cure for idiopathic pulmonary fibrosis available as yet. A large

2. portion of the treatment is directed to provide temporary relieve to the patients.
Failure to provide a complete cure and limited treatment options are considered as
major setbacks of the market. Limited drug options with low efficiency are further
hindering the growth of the global idiopathic pulmonary fibrosis market.
Greater focus on effective drug treatment of idiopathic pulmonary fibrosis has led to
the development of few quality drugs such as Vargatef and Ofev. These drugs
effectively reduce the patient’s discomfort and ease the functioning of the lung. In
addition, increasing R&D programs for development of new therapies to successfully
treat IPF in expected to favor the market in the near future. For instance, recently two
major pharmaceuticals companies Inventiva SAS and Boehringer Ingelheim GmbH
have decided to jointly work on developing potential new treatments for IPF.
Idiopathic Pulmonary Fibrosis Therapeutic Market: Region-wise Analysis
On the basis of region, the global idiopathic pulmonary fibrosis therapeutics market
has been segmented into six key regions namely North America, Latin America,
Western Europe, Eastern Europe, Asia Pacific (APAC), and the Middle East & Africa.
Europe and North America are considered as the two largest market of idiopathic
pulmonary fibrosis therapeutics. In addition, the presence of major pharmaceutical
companies in these two regions has positively impacted the growth of the market.
Countries such as the US, Canada, Germany, France and Britain have accounted for a
healthy demand of idiopathic pulmonary fibrosis therapeutics attributed to the
increasing number of IPF incidence occurring in these countries. The global IPF
therapeutics market is expected to register a healthy growth in the upcoming years.
Sample Brochure Download:
Few of Key players in the global idiopathic pulmonary fibrosis therapeutic market
include AdAlta Pty Ltd., Biogen, Inc., Angion Biomedica Corp., Chong Kun Dang
Pharmaceutical Corp., FibroGen, Inc. Progenra, Inc, Boehringer Ingelheim GmbH and
Vectura Group plc. Most companies the focusing on further product development and
offer a wider range of IPF therapeutic treatments.
About Us
PDF Brochure

3. Transparency Market Research (TMR) is a global market intelligence company
providing business information reports and services. The company’s exclusive blend
of quantitative forecasting and trend analysis provides forward-looking insight for
thousands of decision makers. TMR’s experienced team of analysts, researchers, and
consultants use proprietary data sources and various tools and techniques to gather
and analyze information.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/